Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001893124 | SCV002158340 | likely benign | not provided | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002407011 | SCV002717356 | likely benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2021-11-24 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Clinical Genomics Laboratory, |
RCV004579579 | SCV005062006 | uncertain significance | Schwannomatosis 2 | 2021-07-23 | criteria provided, single submitter | clinical testing | The p.Val602= variant in the LZTR1gene has not been previously reported in association with disease. This varianthas been identified in 1/251,134 chromosomes by the Genome Aggregation Database (http://gnomad.broadinstitute.org/). Although this variant has been seen in the general population, it has not been observed at a frequency high enough to rule out pathogenicity. The p.Val602= variant occurs near the 3’splice site and computational tools do not predictan impact to splicing. However, the accuracy of these computational tools is limited. These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, the significance of the p.Val602= variant is uncertain. Additional information is needed to resolve the significance of this variant.[ACMG evidence codes used: PM2_Supporting] |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004782814 | SCV005394556 | likely benign | not specified | 2024-09-30 | criteria provided, single submitter | clinical testing |